Tag Archives: Barclays

What’s wrong with Celgene as shares get clobbered? Nothing, actually.

The News: Celgene Corp. (Summit NJ) plummeted 20% Thursday (October 26, 2017) to $99.99 after releasing third-quarter earnings. And it wasn’t so much third-quarter revenue, which was up 10% year over year,… Read more »

PTC Therapeutics catches falling knife with Emflaza buy; or did it?

Every now and again I’ll read about what seems on its face a boneheaded business deal between two Pharma companies and try to blow the lid off some super-stealthy, strategic,… Read more »